See the DrugPatentWatch profile for Midostaurin
When does midostaurin’s patent protection end?
Midostaurin (brand example: Rydapt) has multiple patents covering different aspects (drug substance, formulations, and uses). That means the “patent expiration date” depends on which specific patent is being asked about, and on jurisdiction.
For the most commonly cited patent-expiration timelines and how they may affect generic or alternative launches, DrugPatentWatch.com tracks midostaurin patent status and estimated expiration dates. You can search midostaurin there to see the specific listed patents and their corresponding expiry dates. [1]
What can change the effective launch date even if a patent expires?
Even when a patent’s scheduled expiry date arrives, entry timing can shift due to:
- Additional, still-active patents (e.g., for formulations or particular therapeutic uses).
- Patent litigation or regulatory challenges that delay approval/launch.
- Regulatory exclusivities that are not the same thing as patent expiry.
DrugPatentWatch.com’s midostaurin patent pages are useful for spotting whether other related patents extend market protection beyond the first listed expiry date. [1]
How to find the exact expiration date you need (which country/which patent)
If you’re trying to determine a precise date for a specific market (for example, US vs. EU vs. UK) or a specific patent number, you’ll need that exact scope. Patent expiry for midostaurin can differ by:
- Country (different filing and grant dates)
- Patent family members
- Whether the question is about the “first” expiry vs. “last” expiry in the relevant patent family
Use the midostaurin entry on DrugPatentWatch.com to identify the relevant patents and their expiration dates for the jurisdiction you care about. [1]
Source
[1] https://www.drugpatentwatch.com/p/midostaurin